Evicenter
P&T meetings

SKY-0515

Huntington's disease

Last updated
211 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

4 evidence topics · 3 sources

Part C: permitted background HD medications

“Medications used for management for HD may be permitted (at the discretion of the Investigator), if patient commenced medication at least 12 weeks prior to first drug administration and are on a dose regimen that is not anticipated to change during the study” (opens the source at this quote in a new tab)

“participants who have been on a stable dose of the aforementioned therapies for at least 12 weeks prior to screening and who are on a dose regimen that is not anticipated to change during the study may be included (at the discretion of the Investigator).” (opens the source at this quote in a new tab)

Part C: prior HTT-lowering therapy exclusion

“Concurrent enrolment or previous participation at any time in any Huntingtin lowering antisense oligonucleotide, small molecule, gene therapy study.” (opens the source at this quote in a new tab)

Part C: changes in background therapy as intercurrent events

“initiation of a medication that could confound assessment of treatment effect, or a change in background Huntington's disease therapeutic intervention.” (opens the source at this quote in a new tab)

FALCON-HD: prior gene therapy exclusion

“You have had any kind of gene therapy.” (opens the source at this quote in a new tab)

Baseline concomitant medication use in studied participants

No evidence found.